Mirena IUD Lawsuit Background
*We are no longer accepting new Mirena perforation claims.
Manufactured by New Jersey-based Bayer Healthcare Pharmaceuticals, the Mirena IUD (generically known as levonorgestrel) was approved by the FDA for intrauterine contraception in 2000 and is used by approximately 2 million women in the United States alone.
In May 2013, the New Jersey Supreme Court consolidated lawsuits filed in that state alleging that Bayer sold the Mirena IUD in an unsafe, defective and inherently dangerous condition. This decision followed a ruling one month earlier to consolidate federal court lawsuits before U.S. District Judge Cathy Seibel in New York federal court. These cases allege that the Mirena IUD can migrate and perforate the uterine wall.
Later in August 2014, the U.S. Judicial Panel on multidistrict litigation ruled that all Mirena cases alleging idiopathic intracranial hypertension (IIH) will be tried on an individual basis instead of in a consolidated group. The Mirena multidistrict litigation consolidated in New Jersey and New York was not affected by this decision.
After hearing an appeal of an earlier 2016 ruling granted by Judge Cathy Seibel, the U.S. Court of Appeals for the Second Circuit affirmed the dismissal of more than 1,000 claims in the MDL in October 2017. Several state claims continue to move forward.
Our Leadership Roles in Mirena Lawsuits
Attorney Carmen Scott is co-lead counsel for the Mirena multidistrict litigation state court consolidation in New Jersey and is co-chair of the AAJ Mirena® IUD Litigation Group. Motley Rice attorney Fred Thompson serves as co-lead counsel for the Mirena® multidistrict litigation in the U.S. District Court for the Southern District of New York.